Determinants of the availability of hepatitis c testing services in Opioid treatment programs: Results from a national study

Jemima A. Frimpong, Thomas D'Aunno, Lan Jiang

Research output: Contribution to journalArticle

Abstract

Objectives. We examined trends and organizational-level correlates of the availability of HCV testing in opioid treatment programs. Methods. We used generalized ordered logit models to examine associations between organizational characteristics of 383 opioid treatment programs from the 2005 and 2011 National Drug Abuse Treatment System Survey and HCV testing availability. Results. Between 2005 and 2011, the proportion of opioid treatment programs offering HCV testing increased but largely because of increases in off-site referrals rather than on-site testing. HCV testing availability was higher in opioid treatment programs affiliated with a hospital and those receiving federal funds. Opioid treatment programs providing both methadone and buprenorphine were more likely to offer any HCV testing, whereas opioid treatment programs providing only buprenorphine treatment were less likely to offer on-site testing. HCV testing availability was associated with more favorable staff-to-client ratios. Conclusions. The increasing use of off-site referrals for HCV testing in opioid treatment programs likely limits opportunities for case finding, prevention, and treatment. Declines in federal funding for opioid treatment programs may be a key determinant of the availability ofHCVtesting in opioid treatment programs.

Original languageEnglish (US)
JournalAmerican Journal of Public Health
Volume104
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Opioid Analgesics
Hepatitis
Buprenorphine
Referral and Consultation
Personnel Management
Methadone
Financial Management
Substance-Related Disorders
Logistic Models

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

@article{a486c96cc7914734ba4a7d378ab0cb0b,
title = "Determinants of the availability of hepatitis c testing services in Opioid treatment programs: Results from a national study",
abstract = "Objectives. We examined trends and organizational-level correlates of the availability of HCV testing in opioid treatment programs. Methods. We used generalized ordered logit models to examine associations between organizational characteristics of 383 opioid treatment programs from the 2005 and 2011 National Drug Abuse Treatment System Survey and HCV testing availability. Results. Between 2005 and 2011, the proportion of opioid treatment programs offering HCV testing increased but largely because of increases in off-site referrals rather than on-site testing. HCV testing availability was higher in opioid treatment programs affiliated with a hospital and those receiving federal funds. Opioid treatment programs providing both methadone and buprenorphine were more likely to offer any HCV testing, whereas opioid treatment programs providing only buprenorphine treatment were less likely to offer on-site testing. HCV testing availability was associated with more favorable staff-to-client ratios. Conclusions. The increasing use of off-site referrals for HCV testing in opioid treatment programs likely limits opportunities for case finding, prevention, and treatment. Declines in federal funding for opioid treatment programs may be a key determinant of the availability ofHCVtesting in opioid treatment programs.",
author = "Frimpong, {Jemima A.} and Thomas D'Aunno and Lan Jiang",
year = "2014",
doi = "10.2105/AJPH.2013.301827",
language = "English (US)",
volume = "104",
journal = "American Journal of Public Health",
issn = "0090-0036",
publisher = "American Public Health Association Inc.",
number = "6",

}

TY - JOUR

T1 - Determinants of the availability of hepatitis c testing services in Opioid treatment programs

T2 - Results from a national study

AU - Frimpong, Jemima A.

AU - D'Aunno, Thomas

AU - Jiang, Lan

PY - 2014

Y1 - 2014

N2 - Objectives. We examined trends and organizational-level correlates of the availability of HCV testing in opioid treatment programs. Methods. We used generalized ordered logit models to examine associations between organizational characteristics of 383 opioid treatment programs from the 2005 and 2011 National Drug Abuse Treatment System Survey and HCV testing availability. Results. Between 2005 and 2011, the proportion of opioid treatment programs offering HCV testing increased but largely because of increases in off-site referrals rather than on-site testing. HCV testing availability was higher in opioid treatment programs affiliated with a hospital and those receiving federal funds. Opioid treatment programs providing both methadone and buprenorphine were more likely to offer any HCV testing, whereas opioid treatment programs providing only buprenorphine treatment were less likely to offer on-site testing. HCV testing availability was associated with more favorable staff-to-client ratios. Conclusions. The increasing use of off-site referrals for HCV testing in opioid treatment programs likely limits opportunities for case finding, prevention, and treatment. Declines in federal funding for opioid treatment programs may be a key determinant of the availability ofHCVtesting in opioid treatment programs.

AB - Objectives. We examined trends and organizational-level correlates of the availability of HCV testing in opioid treatment programs. Methods. We used generalized ordered logit models to examine associations between organizational characteristics of 383 opioid treatment programs from the 2005 and 2011 National Drug Abuse Treatment System Survey and HCV testing availability. Results. Between 2005 and 2011, the proportion of opioid treatment programs offering HCV testing increased but largely because of increases in off-site referrals rather than on-site testing. HCV testing availability was higher in opioid treatment programs affiliated with a hospital and those receiving federal funds. Opioid treatment programs providing both methadone and buprenorphine were more likely to offer any HCV testing, whereas opioid treatment programs providing only buprenorphine treatment were less likely to offer on-site testing. HCV testing availability was associated with more favorable staff-to-client ratios. Conclusions. The increasing use of off-site referrals for HCV testing in opioid treatment programs likely limits opportunities for case finding, prevention, and treatment. Declines in federal funding for opioid treatment programs may be a key determinant of the availability ofHCVtesting in opioid treatment programs.

UR - http://www.scopus.com/inward/record.url?scp=84901036214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901036214&partnerID=8YFLogxK

U2 - 10.2105/AJPH.2013.301827

DO - 10.2105/AJPH.2013.301827

M3 - Article

C2 - 24825236

AN - SCOPUS:84901036214

VL - 104

JO - American Journal of Public Health

JF - American Journal of Public Health

SN - 0090-0036

IS - 6

ER -